Filing Details

Accession Number:
0000950170-24-032990
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-18 17:45:14
Reporting Period:
2024-03-14
Accepted Time:
2024-03-18 17:45:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP Biological Products, (No Disgnostic Substances) (2836) 473173478
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1968317 Raju Prasad C/O Crispr Therapeutics
105 West First Street
Boston MA 02127
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2024-03-14 10,000 $0.00 10,000 No 4 M Direct
Common Shares Disposition 2024-03-15 3,524 $72.69 6,476 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Restricted Stock Units Disposition 2024-03-14 10,000 $0.00 10,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
  2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
  3. This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.